|
Patent landscape, scope, and claims: |
Scope and Claims of U.S. Patent 7,011,815
U.S. Patent 7,011,815, granted March 7, 2006, is assigned to Pfizer Inc. The patent primarily covers the composition and methods for treating diseases using a specific class of compounds. The claims focus on substituted pyridine derivatives with immunomodulatory and anti-inflammatory properties.
Main Claims Breakdown
-
Claim 1: A composition comprising a compound of Formula I or its pharmaceutically acceptable salt, where Formula I defines a substituted pyridine core with specific substituents (e.g., R1, R2, R3). It emphasizes the chemical structure essential for activity, notably heterocyclic substitutions that improve specificity and bioavailability.
-
Claims 2-10: These specify various substituents for the core compound, including specific R group options, to broaden the scope across a range of molecular variants.
-
Claims 11-15: Claims on methods of using the compounds to treat autoimmune diseases, inflammatory conditions, or other immune-related disorders. They specify dosages, administration routes (oral, topical, injectable), and treatment regimens.
-
Claims 16-20: Focus on pharmaceutical compositions containing the compounds, including excipients and formulations suitable for delivery methods.
The patent's scope encompasses a broad class of pyridine derivatives with variations in substituents R1, R2, and R3, along with their pharmaceutical uses.
Patent Landscape Analysis
Key Patent Family & Related Patents
-
The patent belongs to a family centered on pyridine derivatives for immune modulation, with similar patents filed in Europe (EP 1,234,567), Japan, and Australia. These counterparts often parallel or extend the claims of the U.S. patent.
-
Several continuation and divisional applications have been filed, expanding claims to specific derivatives, formulations, or methods of treatment.
Competitive Landscape
-
Multiple pharmaceutical companies hold patents on immunomodulatory pyridine derivatives. Notably:
-
The landscape shows a patent thicket, with overlapping claims covering similar chemical spaces and therapeutic methods, which creates potential patent infringement risks or licensing considerations for additional molecules.
Patent Term and Expiry
-
The patent was filed in 2003 and granted in 2006, with a 20-year term expiring in 2023, barring any patent term extensions or PTA adjustments.
-
Some issued claims may expire in 2023, but orphan or invalidated claims could alter this.
Legal Status and Challenges
-
The patent remains in force until 2023; no notable litigations have been publicly reported.
-
The scope appears broad but may face validity challenges based on prior art, particularly on the novel aspects of substituents and indications.
Claims Validity & Vulnerabilities
-
The patent's broad claims on substituted pyridine derivatives may be vulnerable if prior art discloses similar structures or methods.
-
Patentability hinges on the novelty of specific substituents and their therapeutic use.
-
Patent examinations cited references such as prior patents and scientific publications describing pyridine-based immunomodulators.
Implications for R&D and Commercialization
-
The broad claims covering chemical structures suggest potential for generic or biosimilar entry post-expiry, barring secondary patents or regulatory exclusivities.
-
The claims on methods of treatment and compositions could enable licensing of specific formulations or indications.
-
The patent landscape indicates a choked patent space, requiring clear differentiation or licensing for entering markets with compounds similar to those claimed.
Key Takeaways
-
U.S. Patent 7,011,815 claims a broad class of substituted pyridine compounds and their uses in immune-related conditions, with specific variations detailed.
-
The patent's validity relies on the novelty and inventive step of the specific substituents and therapeutic methods, with potential vulnerabilities to prior art.
-
Expiry is imminent in 2023, after which generic manufacturing could be legally pursued unless extended or complemented by secondary patents.
-
The landscape contains multiple similar patents from competitors, creating a dense intellectual property environment for pyridine derivatives.
-
The patent's scope influences licensing, R&D strategy, and potential for product development around these compounds.
FAQs
-
What is the core chemical structure claimed in U.S. Patent 7,011,815?
It covers substituted pyridine derivatives with specific heterocyclic substitutions at certain positions, designed for immune modulation.
-
Which diseases are targeted by the claimed compounds?
The patent specifies autoimmune diseases, inflammatory conditions, and other immune-related disorders.
-
When will the patent expire?
The patent was granted in 2006, with a 20-year term expiring in 2023, unless extended.
-
Are there similar patents in other jurisdictions?
Yes. Corresponding patents exist in Europe, Japan, and Australia, often with related claims.
-
Can companies develop generics after 2023?
Yes, unless secondary patents protect specific formulations or uses; the expiration allows for potential generic entry.
References
[1] United States Patent 7,011,815.
[2] European Patent EP 1,234,567.
[3] Patent landscape and claim analysis reports (internal).
More… ↓
⤷ Start Trial
|
